Institut Català de la Salut
[Ramos H, Hernández C, Simó R, Simó-Servat O] Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-06-12T08:04:16Z
2023-06-12T08:04:16Z
2023-05-15
Diabetic retinopathy; Inflammation; Retina
Retinopatia diabètica; Inflamació; Retina
Retinopatía diabética; Inflamación; Retina
The etiology of diabetic retinopathy (DR) is complex, multifactorial and compromises all the elements of the retinal neurovascular unit (NVU). This diabetic complication has a chronic low-grade inflammatory component involving multiple inflammatory mediators and adhesion molecules. The diabetic milieu promotes reactive gliosis, pro-inflammatory cytokine production and leukocyte recruitment, which contribute to the disruption of the blood retinal barrier. The understanding and the continuous research of the mechanisms behind the strong inflammatory component of the disease allows the design of new therapeutic strategies to address this unmet medical need. In this context, the aim of this review article is to recapitulate the latest research on the role of inflammation in DR and to discuss the efficacy of currently administered anti-inflammatory treatments and those still under development.
This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects ICI20/00129 and PI22/01670 and co-funded by the European Union. Hugo Ramos is the recipient of a grant from the Ministerio de Economía y Competitividad (BES-2017-081690).
Article
Versió publicada
Anglès
Retinopatia diabètica; Antiinflamatoris - Ús terapèutic; DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Angiopathies::Diabetic Retinopathy; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Inflammatory Agents; ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::angiopatías diabéticas::retinopatía diabética; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinflamatorios
MDPI
International Journal of Molecular Sciences;24(10)
https://doi.org/10.3390/ijms24108796
info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F01670
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]